论文部分内容阅读
我国少数本土医药制造企业在没有品牌、缺乏政府保护和市场优先权的劣势下逐渐成为医药制造行业中研发与创新活动的主体,它们为了生存和发展,通过选择合作伙伴共同开展研发活动,成功实现了从完全模仿的低端仿制药到首仿药和ME-TOO药开发、最后自主创新地推出国家级甚至国际级创新药物,最终实现了创新绩效的提升。那么,在这类企业的研发活动中,其伙伴的多样性是如何影响企业的创新绩效呢?文章通过对3家医药制造企业的多案例分析,探索了企业的研发伙伴多样性是否以及如何影响其创新绩效,同时,还探讨了影响研发伙伴多样性的前置因素,即战略导向的作用。
Under the condition of no brand, lack of government protection and market priority, a handful of local pharmaceutical manufacturing enterprises in China gradually became the main body of R & D and innovation activities in the pharmaceutical manufacturing industry. In order to survive and develop, they have succeeded in implementing research and development activities through selecting partners From the completely imitated low-end generic drugs to the first generic drug and ME-TOO drug development, the final launch of innovative national or even international innovative drugs, and ultimately to achieve the improvement of innovation performance. How does the diversity of partners affect the innovation performance of enterprises in the R & D activities of such enterprises? The paper explores whether and how the diversity of R & D partners in enterprises is influenced by the multi-case analysis of three pharmaceutical manufacturing enterprises Its innovation performance, at the same time, also discussed the front factors that affect the diversity of R & D partners, that is, the role of strategic guidance.